Navigation Links
Transcription factor is potential target for liver cancer treatment
Date:7/6/2011

AUGUSTA, Ga. Altering the body's metabolism could be an effective treatment for deadly liver cancer, researchers report.

The finding that inhibiting heat shock transcription factor 1, or HSF1, prevents liver cancer in mice also is another wake-up call that a low-fat, healthy diet is an effective cancer deterrent, said Dr. Demetrius Moskophidis, Cancer Virologist/Immunologist at Georgia Health Sciences University. HSF1 and its target genes are important to metabolism regulation.

"The principle that we demonstrated is that if we change the metabolism, we can interfere with tumor growth," said Moskophidis, co-corresponding author on the study published in Cell Metabolism.

GHSU scientists accomplished this by removing HSF1 from the mice; HSF1 inhibitors are under development because of their potential for treating a variety of other cancers such as breast, prostate and kidney cancers.

Liver cancer, among the top-10 cancer killers, is on the increase as obesity leads to fatty livers which predispose to liver cancer. Fat can damage the liver in much the say way as alcohol abuse or hepatitis, two major risk factors for liver cancer.

Removing HSF1 thwarts liver cancer by decreasing access to two critical elements: glucose and lipids or fats.

Tumors use glucose for energy as well as the rapid cell division essential to cancer growth, said Dr. Xiongjie Jin, GHSU Assistant Research Scientist and the study's first author. Cancer also needs more lipids to make membranes needed for new cells and so those cells can communicate, Jin said. Lipids also serve as an additional energy source.

Mice lacking HSF1 are hypersensitive to glucose, able to efficiently turn it into energy that can be used by the body so little can be diverted to cell division, said Dr. Nahid Mivechi, Director of the GHSU Center for Molecular Chaperone, Radiobiology and Cancer Virology and the study's corresponding author. As added bonuses, the mice stay slim even on a high-fat diet and avoid diabetes.

The mice also produce fewer lipids because they more easily make active protein kinase, or AMPK, which helps regulate energy levels and inhibits lipid synthesis, Moskophidis said. Lipid-hungry tumors don't like AMPK, he notes.

The studies, funded by the National Institutes of Health's National Cancer Institute, were done in genetically altered mice that were later exposed to a carcinogen known to produce cancer in 100 percent of male mice within five to seven months. Now the scientists are removing HSF1 from mice that already have cancer to see if this approach which better reflects how treatment would be used in humans works as well. They also are exploring the potential of HSF1 inhibitors in advanced breast cancer and melanoma.

They note that HSF1 levels vary normally, typically increasing after eating. In a high-metabolism, disease state such as cancer, HSF1 becomes more important, Moskophidis said. The researchers believe short-term inhibition of HSF1, as might one day be used in cancer patients, would be safe since it's one of a family of transcription factors with similar functions. However, HSF1 seems to be the family member with the biggest role in cancer.

The football-shaped liver helps the body use food and drink as energy and nutrients and helps detoxify the body. According to the American Liver Foundation, liver cancer tends to be asymptomatic until later stages of the disease. Symptoms may include fatigue, pain on the right side of the upper abdomen or around the right shoulder blade, nausea, loss of appetite, unexplained weight loss or jaundice. It may be discovered during a routine checkup if a doctor feels hard lumps in the abdomen, or incidentally by imaging studies.


'/>"/>

Contact: Toni Baker
tbaker@georgiahealth.edu
706-721-4421
Georgia Health Sciences University
Source:Eurekalert  

Related medicine news :

1. The 3-dimensional transcription film
2. New Electronic Medical Record (EMR) Software, MxChart™, Launched by Medical Transcription Service Provider, MxSecure
3. Medical Transcription Services Provider, MxSecure, Integrates Physician Dictation into New EMR for Carolina Digestive Health Associates
4. Medical Transcription Services and Electronic Health Record Systems Provider, MxSecure, Relocates Headquarters to New, State-of-the-Art Facility
5. Transcription factors may dictate differences between individuals
6. Medical Transcription Services and EHR Provider MxSecure Promotes Tim Erkel to VP, Client Services
7. Update: MedQuist Wins Contract with Detroit Medical Center for Emergency Medicine Transcription at Six Healthcare Organizations
8. MedQuist Wins Contract with Detroit Medical Center for Emergency Medicine Transcription at Six Healthcare Organizations
9. Medical Transcription Services and EHR Provider MxSecure Launches New Enhanced Website with Goal of Improved Physician Productivity
10. HFES sponsors 2012 Symposium on Human Factors and Ergonomics in Health Care
11. Self-referral: A significant factor in imaging growth
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Transcription factor is potential target for liver cancer treatment
(Date:3/30/2017)... WASHINGTON, DC (PRWEB) , ... March 30, 2017 ... ... Truth. , On the eve of Autism Awareness Month, representatives from Organic ... Center, World Mercury Project, Focus For Health Foundation, A Voice for Choice, Moms ...
(Date:3/29/2017)... , ... March 29, 2017 , ... During the last ... provide free screening colonoscopies to eligible individuals in the local community. , Colon ... but regular screenings can detect colon cancer while it is small, confined and easier ...
(Date:3/29/2017)... ... ... pollen is the main cause of hay fever in the United States, with an estimated ... from May to July each year; with the worst time for sufferers being June and ... ( http://www.haymax.us ) provide an effective defense against grass pollen; they are proven in independent ...
(Date:3/29/2017)... Florida (PRWEB) , ... March 29, 2017 , ... ... be hosting several educational opportunities for attending prescribers at the upcoming World Congress, ... Network said, “A4M has always been recognized as the visionary leader in the ...
(Date:3/29/2017)... , ... March 29, 2017 , ... Dr. Angela Cotey, ... orthodontic treatment and accepting new pediatric patients, with or without a referral. Dr. Cotey ... have a better orthodontic outcome and experience. When patients receive early treatment, they may ...
Breaking Medicine News(10 mins):
(Date:3/30/2017)... 2017  Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, ... Phase 2b dose-ranging study of AKCEA-APO(a)-L Rx in ... of the study is to determine the dose level ... a planned Phase 3 cardiovascular outcome study. ... collaboration with Novartis to develop and commercialize drugs to ...
(Date:3/29/2017)... 29, 2017  Bodycad announced today that it ... 510(k) clearance for its Bodycad Unicompartmental Knee System, ... orthopaedic restoration. Bodycad is the first Canadian company ... implant system. Bodycad,s revolutionary Unicompartmental ... of the patient,s unique anatomical features and kinematics. ...
(Date:3/29/2017)... , March 29, 2017 Avelas Biosciences, Inc., a ... diagnosis through treatment, today announced that Carmine N. Stengone , ... company at the Needham & Company 16 th Annual Healthcare ... a.m. PDT) at the Westin Grand Central Hotel in ... ...
Breaking Medicine Technology: